Correction: Tumor-Restricted Activation of Vγ9Vδ2 T Cells via Bispecific Evobodies: A Novel Strategy for Safe and Potent Immunotherapy in Ovarian Cancer

Hans-Heinrich Oberg¹Malte Deseke²Steffen Krohn¹Dorothee Winterberg¹Matthias Peipp¹Dirk Bauerschlag³Klaus-Peter Künkele²Daniela Wesch^1*Christoph Baumann^2*

• ¹Universitatsklinikum Schleswig-Holstein, Kiel, Germany
• ²Evobright GmbH, Vienna, Austria
• ³Universitatsklinikum Jena Klinik und Poliklinik fur Hals Nasen Ohren Heilkunde, Jena, Germany

In the published article, there was a mistake in the Material and Methods section. In the paragraph "Establishment of Vg9Vd2 T cell lines" there was an erraneous concentration of 2.5mM:Peripheral blood lymphocytes (PBL) were isolated from leukocyte concentrates or EDTA blood of healthy or ovarian cancer patient donors using Ficoll-Hypaque™ PLUS (Cytiva) density gradient centrifugation. A total of 1 x 10 6 PBMCs were stimulated with 2.5 mM of the aminobisphosphonate (n-BP) zoledronate (Novartis, Basel, Switzerland) in complete medium. The complete culture medium for primary immune cell culture or assay setup was composed of RPMI 1640 supplemented with 2 mM L-glutamine, 25 mM HEPES, 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% FCS. All cell culture procedures and assay incubation steps were performed at 37°C in a humidified atmosphere with 5% CO2. Activation of PBL with n-BP and IL-2 induced selective activation and proliferation of Vg9Vd2 T cells. Recombinant IL-2 (Novartis) was added every 2 days at a concentration of 50 IU/mL for 14 days, as initially stimulated gd T cells produced only low levels of IL-2. After 14 days, the short-term activated gd T cell lines were stained with the following antibodies: AF700-labeled anti-CD3 clone SK7 (BioLegend, San Diego, CA, USA); AF488-labeled anti-Vg9 clone 7A5 (62) flow cytometry to determine purity. gd T cells with a purity of >95% were used for functional assays.A correction has been made to the section M&M, Establishment of Vg9Vd2 T cell lines: Peripheral blood lymphocytes (PBL) were isolated from leukocyte concentrates or EDTA blood of healthy or ovarian cancer patient donors using Ficoll-Hypaque™ PLUS (Cytiva) density gradient centrifugation. A total of 1 x 10 6 PBMCs were stimulated with 2.5 µM of the aminobisphosphonate (n-BP) zoledronate (Novartis, Basel, Switzerland) in complete medium. The complete culture medium for primary immune cell culture or assay setup was composed of RPMI 1640 supplemented with 2 mM L-glutamine, 25 mM HEPES, 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% FCS. All cell culture procedures and assay incubation steps were performed at 37°C in a humidified atmosphere with 5% CO2. Activation of PBL with n-BP and IL-2 induced selective activation and proliferation of Vg9Vd2 T cells. Recombinant IL-2 (Novartis) was added every 2 days at a concentration of 50 IU/mL for 14 days, as initially stimulated gd T cells produced only low levels of IL-2. After 14 days, the short-term activated gd T cell lines were stained with the following antibodies: AF700-labeled anti-CD3 clone SK7 (BioLegend, San Diego, CA, USA); AF488-labeled anti-Vg9 clone 7A5 (62) flow cytometry to determine purity. gd T cells with a purity of >95% were used for functional assays.The original version of this article has been updated.